FDA approves EPKINLY® to treat patients with follicular lymphoma
AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or …